{'fraction_non_alphanumeric': 0.020604395604395604, 'fraction_numerical': 0.024725274725274724, 'mean_word_length': 5.627272727272727, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Real‐world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006–2019

myelofibrosis. In conclusion, our observations from the current study do not support the consideration of ExT as a risk factor for thrombosis, in otherwise low-risk ET, and question the value of prophylactic cytoreductive therapy in the particular scenario; a similar observation was recently communicated regarding the use of hydroxyurea in ET patients age 40–59 years and without risk factors for thrombosis or platelet count ≥1500 × 10/L; a prospective controlled study is needed for further clarification and confirmation of the observed benefit from aspirin therapy in the current retrospective study.